Brianna Wolin wins Lyfebulb-Novo Nordisk Innovation Award

Brianna Wolin wins Lyfebulb-Novo Nordisk Innovation Award

Copenhagen, 7 December 2016: Brianna Wolin (US), who is CEO and co-founder of Find Your Ditto, wins the first ever Lyfebulb-Novo Nordisk Innovation Award. She receives the award for pioneering an app-based concept that will facilitate virtual and real-life connectivity between people living with the same chronic disease. This app will address a major challenge for people living with rare or invisible chronic diseases, such as type 1 – the disease that Brianna herself lives with.

“To be recognized by an innovative organization such as Lyfebulb and Novo Nordisk, a global pharmaceutical leader in diabetes care, is a true honour and an affirmation that our work to helping change the landscape surrounding isolation and depression in chronic illness communities is fully worthwhile,” said Brianna Wolin. “I’m so proud to have our mission – creating a world where no person living with a chronic illness ever has to feel alone – highlighted by this award.”

Brianna Wolin is one of ten distinguished patient entrepreneur finalists, who were selected as ‘the best-of-the-best’ among more than 100 applicants received for the Award. The other nine finalists are:

Shilo Ben-Zeev, Smartzyme, Israel

Jeff Dachis, OneDrop, USA

Shantanu Gaur, MD, Allurion, USA

Matt Loper, Wellth, USA

Charles O’Connell, FitScript, USA

Scott Smith, Socrates, USA

Anna Sjoberg, Anna PS, Sweden

John Sjolund, Patients Pending Ltd, UK

David Weingard, Fit4D, USA

The decision to award Brianna with the first Lyfebulb-Novo Nordisk Award was taken by a panel of four patient key opinion leaders from the diabetes community.

You can read more about the prize and the Novo Nordisk and Lyfebulb collaboration here:




Lyfebulb partners with Novo Nordisk to support patient-driven innovations for people with diabetes

Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to people living with chronic disease, announces a partnership with Novo Nordisk A/S.

The partnership will focus on patient entrepreneurs developing innovative ideas and concepts for better management of diabetes using consumer or medical devices, or healthcare information technology. Linking entrepreneurs with senior device researchers from Novo Nordisk will spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.  

“This partnership with Novo Nordisk marks a milestone for Lyfebulb as a young organisation with a strong commitment to patient-driven innovation and laser-focus on improving the quality of life for those living with chronic diseases such as diabetes,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “We are excited to expand our Lyfebulb Entrepreneur Circle, which provides exposure to an exclusive group of patient entrepreneurs who seek to truly transform their business.  These entrepreneurs may help to transform the lives of patients.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl stated: “Having the patient at the center of everything we do directs us in our daily work. My team and I look forward to the unique opportunity to learn from and be inspired by the patient entrepreneurs.”


About Lyfebulb

Lyfebulb is a business focused on bringing innovative products and solutions focused on chronic disease to market.  Lyfebulb serves as a bridge between patients and industry, and its mission is to improve the quality of life of those living with chronic disease NOW. 

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.